News Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
45.04 ^USD	+0.24%		+13.14%	+63.78%

04-19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
03-28	Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting	04-24	GL
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	04-19	MT
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024	04-08	GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024	04-08	AQ
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	04-03	GL
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	04-03	AQ
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target	03-28	MT
Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating	03-07	MT
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies	03-06	MT
Gilead, Merus to Collaborate on Trispecific Antibody Research	03-06	DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers	03-06	CI
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression	03-05	GL
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression	03-05	AQ
Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.	03-04	CI
Needham Raises Price Target on Merus to $65 From $42, Keeps Buy Rating	03-04	MT
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference	03-04	GL
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference	03-04	AQ
Merus Full-Year 2023 Net Loss Widens, Revenue Increases	02-28	MT
Earnings Flash (MRUS) MERUS N.V. Posts 2023 Revenue $43.95M	02-28	MT
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update	02-28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Merus N.V.

Equities

MRUS

NL0011606264

Summary

Filters